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Emerging  life  threatening  pathogens  such  as severe  acute  aspiratory  syndrome-coronavirus  (SARS-CoV),
avian-origin  inﬂuenzas  H7N9,  and  the  Middle  East respiratory  syndrome  coronavirus  (MERS-CoV)  have
caused  a  high  case-fatality  rate  and  psychological  effects  on  society  and  the  economy.  Therefore,  a simple,
rapid, and  safe  method  to investigate  a therapeutic  approach  against  these  pathogens  is  required.  In thisvailable online 13 February 2014
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study, a  simple,  quick,  and safe  cell  adhesion  inhibition  assay  was developed  to  determine  the  potential
cellular  binding  site  on  the  SARS-CoV  spike  protein.  Various  synthetic  peptides  covering  the potential
binding  site helped  to minimize  further  the  binding  motif  to 10–25  residues.  Following  analyses,  2 pep-
tides  spanning  the  436–445  and  437–461  amino  acids  of  the  spike  protein  were  identiﬁed  as  peptide
inhibitor  or  peptide  vaccine  candidates  against  SARS-CoV.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  Open access under CC BY-NC-SA license.. Introduction
Severe acute respiratory syndrome (SARS) ﬁrst appeared in
sia in 2002, caused by the SARS-coronavirus (SARS-CoV) (Drosten
t al., 2003; Holmes, 2003; Peiris et al., 2003). The illness quickly
pread worldwide and affected more than 8000 people with a
igh case-fatality rate (Kuehn, 2013). Newly emerging pathogens
uch as the avian inﬂuenza A virus H7N9 (Wu and Gao, 2013)
nd MERS-CoV (Middle East Respiratory syndrome coronavirus,
lso known as HCoV-EMC) (Kuehn, 2013) are severe public health
roblems that cause a high case-fatality rate and widespread psy-
hological effects on society and the economy. A simple method
Abbreviations: SARS-CoV, severe acute respiratory syndrome-coronavirus; S,
pike; RBD, receptor-binding domain; ACE2, angiotensin-converting enzyme
;  RBM, receptor-binding motif; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
iphenyltetrazolium bromide.
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ttp://dx.doi.org/10.1016/j.jviromet.2014.01.022
Open access under CC BY-NC-SAis required to investigate a therapeutic approach to these diseases
without contacting the biohazardous virus.
Previous studies have completed whole genome sequences
(29,751 base pairs) (Marra et al., 2003; Ruan et al., 2003). The data
reveal SARS-CoV to be a novel coronavirus that does not belong to
any of the 3 known classes of coronavirus (Marra et al., 2003). The
genomes encode 23 putative proteins, including known coronavi-
rus proteins such as replicase 1A, replicase 1B, spike glycoprotein
(S), small envelope protein, membrane glycoprotein, and nucleo-
capsid protein (Marra et al., 2003; Ruan et al., 2003). The S gene
[nucleotide (nt) 21,492–25,259] encodes a transmembrane gly-
coprotein on the viral surface and is responsible for binding and
entry into the host cells (Marra et al., 2003). The S protein can
be divided into 2 functional domains: S1 and S2. The S1 domain
contains a receptor-binding domain (RBD) responsible for speciﬁc
binding to the host receptor (Gallagher and Buchmeier, 2001). The
angiotensin-converting enzyme 2 (ACE2) is a functional receptor
for SARS-CoV (Li et al., 2003). After binding to ACE2, conformational
change of the S protein induces exposure of the S2 domain and
assists the virus in fusing to the host cells (Matsuyama and Taguchi,
2002). Therefore, the RBD within the S1 domain is the target for
development of virus-entry blocking peptides and neutralizing
antibodies to prevent SARS-CoV infections. Previous studies have
used various methods to investigate the potential RBD from amino
acids spanning 303–537 (Xiao et al., 2003), 270–510 (Babcock et al.,
 license.
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004), 318–510 (He et al., 2004; Wong et al., 2004), 485–625
Zhou et al., 2004), 261–672 (Sui et al., 2004), 48–358 (Chou et al.,
005), and 450–650 (Zhao et al., 2005), which all span hundreds
f residues. A receptor-binding motif (RBM) (residues 424–494)
ocated within the RBD has been identiﬁed based on the crystal
tructure of the SARS-CoV spike protein RBD (residues 306–527)
ith the receptor ACE2 (Li et al., 2005). However, no effective ther-
peutic agents against SARS-CoV have been developed in humans
Jiang et al., 2013).
In this study, a cell-adhesion inhibition assay was  established
o characterize further the potential RBM of the SARS-CoV S pro-
ein. Synthetic peptides spanning the potential binding site were
sed and the RBM was further narrowed to approximately 10–25
esidues. This method is useful for characterizing the potential RBM
n the RBD of newly emerged coronaviruses in a quick, simple, and
afe manner without contacting life threatening pathogens.
. Materials and methods
.1. Construction of S1-1/pGEX-6P-3, S1-2/pGEX-6P-1, and
1-3/pGEX-6P-1 expression plasmids
Using 2 plasmids encoding the SARS-CoV spike S1
rotein-TW1-#18 [nucleotide (nt) (nt 20,704–22,087)] and
W1-#19 (nt 21,826–22,087) as templates, an S1-1 encod-
ng SARS-CoV S protein 1–446 amino acid was produced
nd ampliﬁed by polymerase chain reaction (PCR), using
ne pair of primers: SS-F1-2 containing the EcoRI site (5′-
GAATTCCATGTTTATTTTCTTATTATTTCTTACTCTCACTAGTGGTAG-
′) and SS-R4-3 containing the HindIII site (5′-
AAGGGCCTAAGCTTGCCATGTCTAAGCTACCTATATTTATAATTATAA
′). Using 2 plasmids encoding the SARS-CoV spike S1
rotein-TW1-#19 (nt 21,826–22,087), the S1 protein and the
2 protein-TW1-#20 (nt 23,077–24,454) as templates, the S1-2
ncoding SARS-CoV S protein 447–641 amino acid was produced
nd ampliﬁed by PCR, using one pair of primers: SS-F3-2 con-
aining the HindIII site (5′-GACATGGCAAGCTTAGGCCCTTT-3′) and
S-R3 containing the SalI site (5′-GAAGTGTCGACATGCTCAGCTC-
′). The PCR products of S1-1 and S1-2 were subsequently
loned into pGEX-6P-3 and pGEX-6P-1 (Amersham Biosciences,
J, USA) through EcoRI/HindIII and HindIII/SalI  digestion and
igation, respectively. The S1-1 fragment was subcloned into
1-2/pGEX-6P-1 through EcoRI/HindIII digestion and ligation
o form S1-3/pGEX-6P-1, using standardized molecular cloning
echnologies (Sambrook et al., 1989).
.2. Protein expression and puriﬁcation
The Escherichia coli culture was performed based on standard
ethods (Sambrook et al., 1989; Liou et al., 2011; Chang et al., 2012;
seng et al., 2013). The glutathione-S transferase (GST)-containing
ecombinant protein expression plasmids S1-1/pGEX-6P-3, S1-
/pGEX-6P-1, S1-3/pGEX-6P-1, and pGEX-2KS (Chang et al., 1993,
002) were transformed into the E. coli strain BL21 (DE3) for
xpression. The induction and puriﬁcation of the recombinant
roteins were performed using methods modiﬁed from previous
tudies (Chang et al., 1993, 1997b, 2000; Chang and Lo, 2000;
un et al., 2007). Bacteria containing the expression plasmids
ere grown in a 2× YT broth (1.6% trypton, 1% yeast extract, and
.5% NaCl) at 37 ◦C. The recombinant proteins were induced by
dding isopropyl -d-1-thiogalactopyranoside (IPTG) (1 mM)  to
he medium after the optical density (OD) of the bacterial cul-
ure reached 1.0. The optimal induction conditions were incubated
t 37 ◦C for 2 h (S1-2/pGEX-6P-1, S1-3/pGEX-6P-1, and pGEX-
KS) and 4 h (S1-1/pGEX-6P-3). For puriﬁcation, the centrifugedical Methods 201 (2014) 1–6
pellets of E. coli cells from a 1-L culture were resuspended in
50 mL  1× phosphate-buffered saline (PBS) containing protease
inhibitors-1 mM phenylmethylsulfonyl ﬂuoride (PMSF), 0.7 g/mL
of pepstatin, 1 g/mL of leupeptin, and 2 mg/mL of lysozyme. The
bacterial cells were subsequently disrupted using a French Press.
The cell lysates were centrifuged at 10,000 × g for 30 min  and
passed through 0.45-m ﬁlters to remove insoluble cell com-
ponents. The ﬁltered-cell lysates were loaded into a glutathione
sepharose 4B column and the ﬂow-through was  again reloaded into
the column to ensure saturated binding. The proteins were eluted
using an elution buffer (10 mM glutathione; 50 mM Tris–HCl, pH
9.6; 1 mM PMSF; 0.7 g/mL of pepstatin, and 1 g/mL of leupeptin)
and dialyzed with 1× PBS containing 1 mM PMSF. Consequently,
all recombinant proteins used in this study were GST tagged. The
protein concentration was determined using a protein assay kit
(Bio-Rad, Hercules, CA, USA).
2.3. Antibody generation and puriﬁcation
New Zealand rabbits were purchased from the National Labo-
ratory Animal Center (Taipei, Taiwan) and maintained in a speciﬁc
pathogen-free condition in the experimental animal center of Tzu
Chi University. The research methods involving the experimental
rabbits were performed under strict adherence to the guidelines of
the Institutional Animal Care and Use Committee (Tzu Chi Univer-
sity) and the guidance of Animal Protection Law (Taiwan). Using
methods modiﬁed from previous studies (Harlow and Lane, 1988;
Chang et al., 2002; Sun et al., 2007), 250–500 g of puriﬁed recom-
binant proteins were mixed with complete Freund’s adjuvant and
injected into New Zealand rabbits for the ﬁrst immunization. For
boosting, 100–250 g proteins were mixed with incomplete Fre-
und’s adjuvant and injected in immunization cycles in 3-week
intervals. After 5 immunizations, sera from rabbits were isolated
and passed through the Protein A column. Immunoglobulin IgG
fractions were eluted using an elution buffer (0.1 M citric acid, pH
3.0) and dialyzed with 1× PBS.
2.4. Synthetic peptides
Synthetic peptides GA91 (corresponding to SARS-CoV Spike
protein 437–461 amino acids) were produced in linear form.
Synthetic peptides GA101 (corresponding to SARS-CoV S protein
436–445 amino acids), GA107 (corresponding to SARS-CoV S pro-
tein 466–475 amino acids), and GA142 (corresponding to SARS-CoV
S protein 100–109 amino acids) were produced in branched mul-
tiple antigenic peptide (M8) form. All synthetic peptides were
provided by Genesis Biotech (Taipei, Taiwan).
2.5. Cell culture and cell-adhesion/inhibition assay
Vero E6 cells (ATCC No. C1008) and HeLa cells (ATCC No. CCL-
2.2) were maintained in RPMI 1640 (BioWest, Miami, FL, USA), and
NIH3T3 cells (ATCC No. CRL-1658) were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (BioWest) containing 10% heat-
inactivated fetal bovine serum (Biological Industries, Beit Haemek,
Israel), 2 mM l-glutamine (BioWest), 100 U/L of penicillin (BioW-
est), 100 mg/mL  of streptomycin (BioWest), and non-essential
amino acid (BioWest). Cell adhesion and inhibition assays were
performed according to our previously described methods (Chang
et al., 1993, 1997a; Chang and Lo, 1998; Chang et al., 1999, 2001,
2002, 2003; Chang et al., 2005; Sun et al., 2005; Chang and Lo,
2007). Recombinant proteins (1.2 g/30 L/cover slip) were coated
on cover slips at 37 ◦C for 1 h in 6-well microtiter plates, and then
blocked with 5% bovine serum albumin (BSA) at 37 ◦C for a further
hour. After being washed twice with PBS, cells (1 × 106) pre-mixed
with antibodies (75 g) or synthetic peptides (10 nmol) at 37 ◦C
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Fig. 1. Relative locations of SARS-CoV spike protein fragments S1-1 (1–446), S1-2
(447–641), and S1-3 (1–641) and related peptides. Using 3 plasmids encoding the
SARS-CoV spike S1 and S2 proteins, TW1-#18, TW1-#19, and TW1-#20, as tem-
plates, S1-1 encoding the SARS-CoV S protein 1–446 amino acids and S1-2 encoding
the SARS-CoV S protein 446–641 amino acids was  produced and ampliﬁed using
PCR,  using 2 primers: SS-F1-2 and SS-R4-3, and SS-F3-2 and SS-R3, respectively.
The PCR products of S1-1 and S1-2 were subcloned into pGEX-6P-3 and pGEX-6P-1
to  form S1-1/pGEX-6P-3 and S1-2/pGEC-6P-1. The S1-1 fragment was subcloned
into S1-2/pGEX-6P-1 to form S1-3/pGEX-6P-1. Synthetic peptides GA91 (spanning
437–461 amino acids of the SARS-CoV S protein), GA101 (spanning 436–445 amino
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Fig. 2. The SARS-CoV S protein fragment S1-3 signiﬁcantly accelerated the cell adhe-
sion of Vero E6 cells and this effect can be inhibited by anti-S1-1 and anti-S1-2
antibodies. Recombinant proteins GST, S1-2, and S1-3 (1.2 g) were coated on cover-
slips in a 6-well dish, which was blocked with 5% bovine serum albumin. Vero E6
cells were seeded onto recombinant S protein-coated cover-slips and a binding assay
was subsequently performed (A, a–c). For the inhibition assay, Vero E6 cells were
pre-mixed with antibodies (75 g) and seeded onto S1-3 pre-coated cover-slips (A,
d–f). Cell images were captured using an inverted microscope at 100× magniﬁca-
tion. The adherent cells were counted from 3 randomly selected (nonoverlapping)
ﬁelds of each condition. The average cell counts of adherent cells in the GST-coated
groups served as controls and deﬁned as 100%. The percentages of adherent cellscids of the SARS-CoV S protein), GA107 (spanning 466–475 amino acids of the
ARS-CoV S protein), and GA142 (spanning 100–109 amino acids of the SARS-CoV
 protein) are shown in the black boxes.
or 30 min  were seeded onto pre-coated cover-slips and grown in
edium at 37 ◦C for 45 min. After being washed twice with PBS,
ells were ﬁxed with 4% paraformaldehyde (in 1× PBS) at room
emperature for 30 min. After being washed with PBS again, the
ells were examined using an inverted microscope (Axiovert 40
FL, Carl Zeiss, Gottingen, Germany) and photographed.
. Results
.1. Construction of expression plasmids for the SARS-CoV spike
rotein
The cell adhesion assay required recombinant proteins of
he S1 domain and corresponding antibodies. Previous studies
ave reported that prokaryotic expressed non-glycosylated recom-
inant S proteins retained their function (Zhou et al., 2004;
hakraborti et al., 2005; Zhao et al., 2005). In this study, different
ragments of the S1 domain (S1-1, S1-2, and S1-3) were con-
tructed into E. coli expression vectors and expressed as glutathione
-transferase (GST)-fusion proteins (Fig. 1). S1-1 and S1-2 recom-
inant proteins, encompassing amino acids 1–446 and 447–641 of
he S protein, were used to immunize rabbits for 5 immunization-
ycles to obtain corresponding antibodies.
.2. Determination of potential binding site of SARS-CoV spike
roteins by using a cell adhesion assay
Previous studies have shown that SARS-CoV can infect the kid-
ey cells of the African green monkey (Vero E6) (Li et al., 2003;
arra et al., 2003). Puriﬁed GST, S1-3, and S1-2 recombinant
rotein-coated cover slips and Vero E6 cells were used to perform a
ell adhesion assay. The cell-adhesion efﬁciency of Vero-E6 cells to
1-3 coated cover slips were approximately 1.5 to 1.7-fold higher
han that on GST-coated controls (Figs. 2A-a-b, B, 4A-a-b, and B).
hese results indicate that E. coli-derived S1-3 contains functional
BD for Vero E6 cells. In contrast, the efﬁciency of cell adhesion on
1-2 coated substrates is less than that of substrates coated with
he control protein GST (Fig. 2A-c and B). The cell adhesion of Veroare shown in (B). *P < 0.05, **P < 0.01 compared with the control groups. Data are
reported as the mean ± standard deviation (SD).
E6 on S1-3 coated substrates could be inhibited by rabbit polyclonal
antibodies against S1-1 and S1-2, but cannot be inhibited by control
antibodies against GST (Fig. 2A-d–f and B). These results indicated
that the RBD potentially locates around the S1-1 and S1-2 junction
region.
3.3. The permissive cell line Vero E6 but not the non-permissive
cell lines HeLa and NIH 3T3 adhere to SARS-S coated surfaces
To verify whether the S protein-mediated cell adhesion is
speciﬁc to SARS-CoV permissive cells (e.g., Vero E6 cells), 2
SARS-CoV nonpermissive cell lines, HeLa and NIH3T3 [which
cannot be infected by SARS-CoV (Wang et al., 2004)], were used as
controls to perform the cell adhesion assay. The cell-adhesion efﬁ-
ciency of NIH3T3 or HeLa cells to GST and S1-3 coated substrates
did not show signiﬁcant differences (Fig. 3). This suggests that
4 H.-H. Chang et al. / Journal of Virolog
Fig. 3. SARS nonpermissive cell lines (NIH3T3 and HeLa) have no preferential cell
adhesion to the GST-tagged SARS-CoV S protein fragment S1-3 when compared
with the GST control protein. Recombinant proteins GST (A-a and A-c) and S1-3
(A-b and A-d) (1.2 g) were coated on cover-slips in 6-well dishes. NIH3T3 (A, left
panel) and HeLa cells (A, right panel) were seeded onto recombinant protein pre-
coated cover-slips and performed binding assay. Cell images were captured using
an  inverted microscope at 100× magniﬁcation. The adherent cells were counted
from 3 randomly selected (nonoverlapping) ﬁelds of each condition. The average
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Hell  counts of adherent cells in the GST-coated groups served as controls. The per-
entages of adherent cells of the NHI3T3 and HeLa cells groups are shown in (B) and
C),  respectively. Data are reported as the mean ± SD.
1-3-mediated cell adhesion can be speciﬁcally applied on
ARS-CoV permissive cells.
.4. The minimum binding site can be determined using peptides
n the inhibition assay for cell adhesion
To narrow down the RBD of S protein, several synthetic peptides
orresponding to the S1-1 and S1-2 junction region were used to
erform the inhibition assay for cell adhesion. Our data revealed
hat synthetic peptides GA91 (spanning residues 437–461) and
A101 (spanning residues 436–445) inhibit the cell adhesion of
ero E6 cells on S1-3 coated substrates. GA107 (spanning residues
66–475) exerted a smaller inhibitory effect than GA91 and GA101
id in the cell binding assay. GA42 (spanning residues 100–109)
ncompassing amino acid residues outside the junction between
1-1 and S1-2 exerted only minor inhibition effects in the cell bind-
ng assay (Fig. 4).
. Discussion
In this study, a simple, quick, and safe method was  established
o narrow down the RBM within the RBD of SARS-CoV S protein.
ost popular methods investigating the RBD of SARS-CoV S identify
ragments of SARS S protein binding to cells by using ﬂow cytom-
try analysis (Babcock et al., 2004; He et al., 2004; Sui et al., 2004;
ong et al., 2004; Zhou et al., 2004) and an immunoﬂuorescencessay (Chou et al., 2005; Ho et al., 2006), or determine the binding
etween ACE2 protein and S protein by using an enzyme-linked
mmunosorbent assay (ELISA) (Xiao et al., 2003; He et al., 2004;
o et al., 2006). Although the cell adhesion assay developed in thisical Methods 201 (2014) 1–6
study might not provide high quantitative and sensitive data that
matches the ﬂow cytometry (Babcock et al., 2004; He et al., 2004;
Sui et al., 2004; Wong et al., 2004; Zhou et al., 2004) and ELISA-
based analyses (Xiao et al., 2003; He et al., 2004; Ho et al., 2006),
the analysis only requires recombinant proteins, peptides, virus
permissive cells, and an ordinary light microscope to accomplish.
Consequently, expensive equipment such as the ﬂow cytome-
ter, ﬂuorescence microscope, and ELISA/ﬂuorescence microplate
readers are unnecessary, and this assay can be easily conducted
in general laboratories, including those in third world countries.
Because cell adhesion can be easily measured using MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow
tetrazole] assays, this method has the potential of being developed
as a high throughput screening system for small molecule inhibitors
when combined with automatic and robotic systems, which are
unsuitable for ﬂow cytometry and the immunoﬂuorescence micro-
scope based-assay. ELISA is also available for high throughput or
fast screening systems; however, the recombinant ACE2 protein
may not completely present as the native form of ACE2 on the sur-
faces of SARS-CoV permissive cells. ELISA-based analyses are only
suitable to conduct after identifying the cellular receptor, for exam-
ple after identifying ACE2; however, this study demonstrated that
the novel cell-adhesion approach can be conducted even before
identifying the cellular receptor.
For unknown reasons, the cell adhesion of Vero E6 cells to SARS-
S (S1-2) substrates, which do not contain the RBD, with a lower
efﬁciency than that of control protein GST (Fig. 2). The functional
comparisons between different but related cell-adhesion proteins
are difﬁcult. For example, previously we  found that even a sin-
gle alanine insertion in various places around the cell-binding
motif RGD (R: arginine; G: glycine; D: aspartic acid) of the snake-
venom-protein rhodostomin could result a dramatically difference
of cell-adhesion property. An alanine insertion at position 56
(between 56th and 57th amino acid of rhodostomin) could disrupt
the cell-adhesion function of rhodostomin, while single inser-
tions at positions 45–55 were not (Chang et al., 2001). Because
the remaining protein backbone is unchanged in this case, these
results suggest that the protein structure of rhodostomin is the key
determinant of cell-adhesion function. Even though, the protein
backbone may  play an important role in other conditions. For exam-
ple, evidences indicate that positive charge poly-amino acids such
as poly-lysine can serve as a cell adhesion component (Mazia et al.,
1975; Rajnicek et al., 1998; Brynda et al., 2005). In addition, net
positive charge of cell-attached substratum seems to play a pos-
itive role on lamellipodia, ﬁlopodia formation, cell-adhesion and
cell-growth (Rajnicek et al., 1998; Brynda et al., 2005). As a result,
after analyzing the amino acid sequences of recombinant GST-S1-2
and GST proteins, which encoded by S1-2/pGEX-6P-1 and pGEX-
2KS, respectively, we found that pGEX-2KS-encoded GST contains
more positive-charge amino acids than S1-2/pGEXT-6P-1-encoded
GST-S1-2 (GST: 13%; GST-S1-2: 10%). These phenomena, which
include differences on the protein structures and positive changes,
may  explain the reason why  cell adhesion to GST-substrates was
more efﬁcient than that of GST-S1-2-substrates. Nonetheless, fur-
ther functional and structural investigations are needed to address
the possibilities. Despite of this, the assay in our condition has a
great resolution power (with high reproducibility and signiﬁcantly)
to distinguish the levels of cell adhesion when RBD-containing pro-
teins were used. This suggests that the analysis system has great
potentials on the analysis of RBD of viral proteins.
Using this method, our data suggest that peptides spanning
residues 436–445 and 437–461 of the S protein are the minimal
size of peptides to block the binding of the SARS-CoV S protein
to Vero-E6 cells. These peptides are located within the hundred-
amino-acids RBDs previously identiﬁed using other methods (Xiao
et al., 2003; Babcock et al., 2004; He et al., 2004; Sui et al., 2004;
H.-H. Chang et al. / Journal of Virological Methods 201 (2014) 1–6 5
Fig. 4. The SARS-CoV S protein fragment S1-3-mediated cell adhesion can be inhibited by peptides within the receptor binding domain. Recombinant proteins S1-3 (A, b–h)
(1.2  g) were coated on cover-slips in a 6-well dish. Vero E6 cells were pre-mixed with 75 g of anti-S1-2 antibodies, 10 nmol synthetic peptides GA91 (A–d), GA101 (A–e),
GA107 (A–f), GA101 + GA107 (A–g), and GA142 (A–h) and seeded onto S1-3 pre-coated cover-slips to perform the binding inhibition assay. Cell images were captured using
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Bn  inverted microscope at 100× magniﬁcation. The adherent cells were counted fro
f  adherent cells in the GST-coated groups served as controls. The percentages of ad
re  reported as the mean ± SD.
ong et al., 2004) and are within the RBM (residues 424–494)
haracterized by the crystal structure of the SARS-CoV S pro-
ein (residues 306–527) and the ACE2 complex (Li et al., 2005).
hese peptides also overlap with a hexapeptide (residues 438–443),
hich blocks viral entry into host cells through ACE2 (Struck et al.,
012). These peptides cover most parts of the putative high anti-
enicity site (residues 426–456) reported by the Hsiang CY group
Ho et al., 2004). These peptides are useful as peptide inhibitors and
re optimal candidates for developing the SARS peptide vaccine.
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